Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0622 • ACR Convergence 2024
Translation, Adaptation and Validation of the Brazilian-Portuguese Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) Version: Partial Results from a Single Centre
Clarice Mata Machado, Cristina Lanna, Juliana Garrido, Fabiana Moura and Rosa Telles, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Background/Purpose: In recent years, several indices of disease activity in SLE have been proposed. The Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) showed a high…
Abstract Number: 0643 • ACR Convergence 2024
Using FDG PET Brain Scans and Deep Learning Analyses to Identify a Specific Network Correlated with Cognitive Impairment in SLE
Nha Nguyen¹, An Vo¹, Chris Tang¹, Erik Anderson², Cynthia Aranow², Betty Diamond³, David Eidelberg¹ and Meggan Mackay⁴, ¹Feinstein Institutes, Manhasset, NY, ²Feinstein Institutes for Medical Research, New York, NY, ³The Feinstein Institutes for Medical Research, Manhasset, NY, ⁴Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Cognitive impairment (CI) is a debilitating, untreatable problem for up to 80% of individuals with SLE and human and mouse data suggest multiple SLE-related…
Abstract Number: 0659 • ACR Convergence 2024
Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial
Richard Furie¹, Jorge A. Ross Terres², Elsa Martins³, Imran Hassan⁴, Thomas Schindler³, Jay Garg⁵, William F. Pendergraft III⁶, Ana Malvar⁷ and Brad Rovin⁸, ¹Northwell Health, Manhasset, NY, ²Genentech, Inc,, San Francisco, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴Hoffmann-La Roche Ltd, Mississauga, Canada, ⁵Genentech, Inc., South San Francisco, CA, ⁶Genentech, Inc., Chapel Hill, NC, ⁷Organización Médica de Investigación, Buenos Aires, Argentina, ⁸The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN) is the most common severe organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, placebo-controlled, Phase II NOBILITY trial (NCT02550652) demonstrated…
Abstract Number: 0809 • ACR Convergence 2024
The Utility of the sFlt1:PlGF Ratio to Rule out and Predict Preeclampsia in Women with Lupus
Megan Clowse¹, Kateena Addae-Konadu², Jerome Federspiel³, Jennifer Gilner², Andra James², Eugene Kovalik², Anika Lucas³, Laura Neil², Catherine Sims⁴, Amanda Snyderman², Samir Soneji² and Amanda Eudy⁵, ¹Duke University, Chapel Hill, NC, ²Duke University School of Medicine, Durham, ³Duke University School of Medicine, Durham, NC, ⁴Duke University, Knightdale, NC, ⁵Duke University, Raleigh, NC
Background/Purpose: Women with SLE have high rates of preeclampsia caused by poor placental vascularization. The FDA recently approved the ratio of two angiogenic factors, soluble…
Abstract Number: 0909 • ACR Convergence 2024
Identifying Predictive Serum Soluble Mediators Signatures Specific to ANA+ at Risk of SLE Individuals with Next Generation Proteomics
Aleksandra Bylinska¹, Miles Smith¹, Rufei Lu¹, Benjamin Jones², Carla Guthridge¹, Matthew Caleb Marlin¹, Christian Wright³, Susan Macwana³, Wade DeJager³, Marci Beel³, Christopher Lessard¹, Cristina Arriens¹, Joan Merrill⁴, Judith James¹ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma State University, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation, Oklahoma City 73104, OK
Background/Purpose: Multiple factors can predispose individuals to development of SLE, including the presence of African American ancestry, lupus-associated autoantibodies (ANAs), or some clinical manifestations of…
Abstract Number: 1065 • ACR Convergence 2024
A Quality Improvement Project to Improve Contraception Management in Patients with Systemic Lupus Erythematosus on Teratogenic Medications
Marta Bean¹, Brian Coburn¹, Thomas Riley², Elise Breed¹, Carlos M García-González¹, Akash Gupta¹, Jonathan Kotzin¹, Adam Mayer³, John Oghene¹, Ellen Romich⁴, Michael George¹, Rachel Dayno¹, Nora Sandorfi¹, Preethi Thomas¹ and Anupama Shahane¹, ¹University of Pennsylvania, Philadelphia, PA, ²Hopsital of the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ⁴University of Pennsylvania, Media, PA
Background/Purpose: Many patients with systemic lupus erythematosus (SLE) require teratogenic medications for management of their disease. Reliable contraception is important to avoid unintended pregnancy in…
Abstract Number: 1271 • ACR Convergence 2024
Linkage of the Childhood Arthritis and Rheumatology Research Alliance Registry with the Pediatric Health Information System: Creation of a Comprehensive Childhood-Onset Lupus Dataset
Jordan Roberts¹, Anna Faino², Min-Lee Chang³, Jonathan Cogen⁴, Matt Hall⁵ and Esi Morgan¹, and for the CARRA Registry Investigators, ¹Seattle Children's Hospital, Seattle, WA, ²Seattle Children's Research Institute, Core for Biostatistics, Epidemiology and Analytics in Research, Seattle, ³Computational Health Informatics Program, Boston Children’s Hospital, Boston, MA, ⁴Seattle Children’s Hospital, Seattle, WA, ⁵Children’s Hospital Association, Lenexa, KS
Background/Purpose: Currently, no comprehensive national multipayer dataset with inpatient and outpatient data exists for childhood rheumatologic diseases, limiting the ability to study outcomes longitudinally and…
Abstract Number: 1487 • ACR Convergence 2024
Pregnancy Outcome and Risk Factors Analysis in Patients with Systemic Lupus Erythematosus Complicated with Thrombocytopenia
Fan Lian and Qingying Fang, First Affiliated Hospital of Sun Yat-sen University, guangzhou, China (People's Republic)
Background/Purpose: To compare the pregnancy outcomes of patients with systemic lupus erythematosus (SLE) complicated with thrombocytopenia and those without, and to analyze the related risk…
Abstract Number: 1504 • ACR Convergence 2024
Novel Analytes Associated with Cognitive Impairment in Patients with Systemic Lupus Erythematosus: Serum S100A8/A9, MMP-9 and IL-6
Emma Neary¹, Carolina Munoz-Grajales², Joan Wither³, Juan Pablo Diaz Martinez³, Michelle Barraclough⁴, Kathleen Bingham³, Roberta Kretzmann³, Maria Carmela Tartaglia⁵, Lesley Ruttan⁶, May Choi⁷, Simone Appenzeller⁸, Sherief Marzouk³, Dennisse Bonilla³, Patti Katz⁹, Dorcas Beaton¹⁰, Robin Green³, Laura Patricia Whittall Garcia³, Dafna Gladman¹¹ and Zahi Touma¹², ¹McGill University, Montreal, QC, Canada, ²UHN/TWH, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴The University of Manchester, Manchester, United Kingdom, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Toronto Rehab/University Health Network - University Centre, Toronto, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Unicamp, Campinas, SP, Brazil, ⁹UCSF, San Rafael, CA, ¹⁰Institute for Work & Health, Toronto, ON, Canada, ¹¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹²University of Toronto, Toronto, ON, Canada

Background/Purpose: Cognitive impairment (CI) is an increasingly prevalent neuropsychiatric manifestation in patients with systemic lupus erythematosus (SLE). Although CI has been identified through patient-reported outcomes…
Abstract Number: 1520 • ACR Convergence 2024
The Influence of Trauma on Features of Type 2 SLE
Jennifer Rogers¹, Megan Clowse², David Pisetsky³, Jayanth Doss⁴, Mithu Maheswaranathan⁵, Lisa Criscione-Schreiber⁵, Rebecca Sadun⁴, Kai Sun⁴ and Amanda Eudy⁶, ¹Duke, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Durham, NC, ⁵Duke University School of Medicine, Durham, NC, ⁶Duke University, Raleigh, NC
Background/Purpose: Type 2 SLE symptoms of fatigue, widespread pain, sleep and cognitive dysfunction occur commonly in SLE although their etiology is unknown. Since trauma has…
Abstract Number: 1539 • ACR Convergence 2024
Effectiveness & Safety of Early versus Late Use of Rituximab in Extra-renal Lupus: Real World Experience from a Tertiary Care Centre
JOHN KUMAR DAS¹, ABHILASHA ARVIND MANWATKAR² and JOHN MATHEW², ¹Christian Medical College, Vellore, India, ²christian medical college, vellore, Tamil Nadu, India
Background/Purpose: Rituximab, a monoclonal antibody targeting CD20 positive B cells failed to show effectiveness in SLE, including EXPLORER and LUNAR trials.However, real world data in…
Abstract Number: 1646 • ACR Convergence 2024
A Novel E3 Ligase of GILZ: Validation of a Steroid-sparing Therapeutic Target in SLE
Iolanda Miceli¹, Rochelle Sherlock², Pamela Hall², IanIan Cheang², Akshay D'Cruz³, Taylah Bennett², Terry Lim Kam Sian², Rangi Kandane-Rathnayake⁴, Eric Morand⁵ and Sarah Jones², ¹Monash University, Glen Iris, Victoria, Australia, ²Monash University, Melbourne, Australia, ³Monash University, Me, Australia, ⁴Monash University, Clayton, Victoria, Australia, ⁵School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: SLE is primarily mediated by B cell dysregulation on a background of type I interferon (IFN) activation. This multi-faceted nature of immune defects in…
Abstract Number: 1751 • ACR Convergence 2024
Precision Targeting of Autoreactive 9G4 B Cells in Systemic Lupus Erythematosus Using Engineered Chimeric Antigen Receptor (CAR)- and Chimeric T Cell Receptor (cTCR)-T Cells
Jin Liu¹, Brian Mog¹, Yuanxuan Xia¹, Elana Shaw¹, Alexander Pearlman¹, Dylan Ferris¹, Kyle J. Kaeo¹, Colin Gliech¹, Tolulope Awosika¹, Brock Moritz¹, Tushar Nichakawade¹, Yang Li¹, Stephanie Glavaris¹, Sarah DiNapoli¹, Nikita Marcou¹, Taha Ahmedna¹, Victoria Duarte Alvarado¹, Denis Wirtz¹, Regina Bugrovsky², Scott A. Jenks², Iñaki Sanz³, Daniel Goldman⁴, Michelle Petri⁴, Chetan Bettegowda¹, Suman Paul¹, Kenneth W. Kinzler¹, Shibin Zhou¹, Felipe Andrade⁵, Bert Vogelstein¹ and Maximilian F. Konig¹, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²Emory University School of Medicine, Atlanta, GA, ³Emory University School of Medicine, Atlanta, ⁴Johns Hopkins University School of Medicine, Timonium, MD, ⁵The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: The autoreactive B cell compartment in systemic lupus erythematosus (SLE) is characterized by expansion of B cells expressing immunoglobulin heavy variable gene 4-34 (IGHV4-34)…
Abstract Number: 1791 • ACR Convergence 2024
A Transcriptomic Lupus Activity Signature Associates with Cardiovascular Function
Matthew Muller¹, Elliot Luttrell-Williams¹, Haley Rosmann², Kelly Ruggles³, Jill Buyon⁴ and Jeffrey Berger¹, ¹NYU Langone, New York City, NY, ²NYU Grossman School of Medicine, New York, NY, ³NYU Grossman School of Medicine, Brooklyn, NY, ⁴New York University Grossman School of Medicine, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disorder associated with increased cardiovascular risk. Platelet activity is increased in SLE and may mediate, in…
Abstract Number: 1811 • ACR Convergence 2024
The Immune Map of Lupus Nephritis: A Spatially Resolved Kidney Proteomic Approach
Chen-Yu Lee¹, Matthew Caleb Marlin², Xiaoping Yang¹, Alessandra Ida Celia³, Vasileios Morkotinis⁴, Richard Furie⁵, Jill Buyon⁶, Chaim Putterman⁷, Jennifer Barnas⁸, Kenneth Kalunian⁹, Peter Izmirly¹⁰, Betty Diamond¹¹, Anne Davidson¹², Diane Kamen¹³, Jeff Hodgin¹⁴, the Accelerating Medicines Partnership RA/SLE¹⁵, Judith James², Michelle Petri¹⁶, Joel Guthridge², Avi Rosenberg¹ and Andrea Fava¹, ¹Johns Hopkins UNiversity, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Sapienza University of Rome, Rome, Italy, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Northwell Health, Manhasset, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Albert Einstein College of Medicine, Safed, Israel, ⁸University of Rochester, Rochester, NY, ⁹University of California San Diego, La Jolla, CA, ¹⁰New York University Grossman School of Medicine, New York, NY, ¹¹The Feinstein Institutes for Medical Research, Manhasset, NY, ¹²Feinstein Institutes for Medical Research, Manhasset, NY, ¹³Medical University of South Carolina, Charleston, SC, ¹⁴University of Michigan, Michigan, ¹⁵multiple, multiple, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Treatment response rates in lupus nephritis (LN) remain suboptimal, highlighting the need for a better understanding of LN pathogenesis to enhance treatment strategies. Single-cell…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.